drug · small molecule
BORTEZOMIB
Phase 2updated 6mo agoby Millennium Pharmaceuticals Inc🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for multiple myeloma and mantle cell lymphoma and 36 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying BORTEZOMIB
- phase2Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
- phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
- phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
- phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- phase1A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- phase3A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- phase2A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
News(1)
- Dr Chari on Frontline Combinations and Transplant Approaches in Multiple MyelomaAjai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.onclive · 6mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that